Pathogenesis and Treatment of Myeloma-Related Bone Disease

Pathogenesis and Treatment of Myeloma-Related Bone Disease

Multiple myeloma is a hematologic malignancy of plasma cells that causes bone-destructive lesions and associated skeletal-related events (SREs). The pathogenesis of myeloma-related bone disease (MBD) is the imbalance of the bone-remodeling process, which results from osteoclast activation, osteoblas...

Full description

Bibliographic Details
Main Authors:	Yuh-Ching Gau, Tsung-Jang Yeh, Chin-Mu Hsu, Samuel Yien Hsiao, Hui-Hua Hsiao
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	International Journal of Molecular Sciences
Subjects:	myeloma myeloma bone disease osteoclastogenesis bisphosphonates denosumab novel agents
Online Access:	https://www.mdpi.com/1422-0067/23/6/3112

Similar Items

Management of Myeloma Bone Lesions
by: Jeng-Shiun Du, et al.
Published: (2021-03-01)

Differences in interactions with the bone microenvironment between solid tumors and multiple myeloma: pathogenetic aspects. Possibilities and effectiveness of osteomodifying agents in multiple myeloma
by: A. V. Snegovoy, et al.
Published: (2021-04-01)

Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
by: Sonia Vallet, et al.
Published: (2018-10-01)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
by: Zachary S. Bernstein, et al.
Published: (2022-07-01)

Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma
by: Petra Rugani, et al.
Published: (2016-09-01)

Treatment of bone complications in multiple myeloma patients
by: V. V. Ptushkin
Published: (2022-11-01)

Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2
by: Chia-Hung Yen, et al.
Published: (2020-09-01)

The importance of retaining physical functions to prevent skeletal‐related events in multiple myeloma patients with bone disease
by: Hirokazu Miki, et al.
Published: (2022-05-01)

Basic and clinical associations between bone and cancer
by: Fang He, et al.
Published: (2020-07-01)

TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
by: Hua Bai, et al.
Published: (2018-10-01)

Pathogenesis and treatment of multiple myeloma bone disease
by: Masahiro Hiasa, et al.
Published: (2021-11-01)

Use of bone‐modifying agents and clinical outcomes in older adults with multiple myeloma
by: Adam J. Olszewski, et al.
Published: (2019-11-01)

Game of Bones: How Myeloma Manipulates Its Microenvironment
by: Tyler Moser-Katz, et al.
Published: (2021-02-01)

Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer
by: Stella D’Oronzo, et al.
Published: (2020-04-01)

Osteodestruction markers and quality of life parameters at pomegara (pamidronate) treatment in multiple myeloma patients with lytic bone lesions
by: V. V. Lunin, et al.
Published: (2022-11-01)

Bone metastases: an overview
by: Filipa Macedo, et al.
Published: (2017-05-01)

Bone metastases: Are we failing our patients?
by: B. Tombal, et al.
Published: (2014-05-01)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
by: Jeng-Shiun Du, et al.
Published: (2022-01-01)

Multiple myeloma: Looking beyond standards
by: Esha Kaul, et al.
Published: (2016-01-01)

Amelioration of Paget Disease of Bone After Denosumab for Osteopenia
by: Vijayvardhan Kamalumpundi, BS, et al.
Published: (2023-09-01)

Myeloma Bone Disease: The Osteoblast in the Spotlight
by: Rebecca E. Andrews, et al.
Published: (2021-09-01)

The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
by: Christian Bacci, et al.
Published: (2021-01-01)

Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease
by: Alaa A. Omran, et al.
Published: (2022-06-01)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
by: Patricia Maiso, et al.
Published: (2021-05-01)

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
by: Arthur Bobin, et al.
Published: (2020-10-01)

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review
by: María-Victoria Mateos, et al.
Published: (2020-03-01)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
by: Carlos Bravo-Pérez, et al.
Published: (2021-08-01)

Multiple Myeloma Associated Bone Disease
by: Stine Rasch, et al.
Published: (2020-07-01)

Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era
by: Aya Nakaya, et al.
Published: (2017-02-01)

The Synthetic Collagen-Binding Peptide NIPEP-OSS Delays Mouse Myeloma Progression
by: Syed Hassan Mehdi, et al.
Published: (2023-04-01)

The history of cancer pain and bone-targeted agents: 10 most commonly asked questions
by: Vieira CMP, et al.
Published: (2018-12-01)

New Treatment Methods in Multiple Myeloma
by: Jakab Szende, et al.
Published: (2017-06-01)

Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool
by: Kamal Kant Sahu, et al.
Published: (2022-11-01)

Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents
by: Tomoaki Fukui, et al.
Published: (2023-06-01)

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
by: Jordan Nunnelee, et al.
Published: (2022-05-01)

Myeloma Bone Disease: A Comprehensive Review
by: Shiva Kumar Reddy Mukkamalla, et al.
Published: (2021-06-01)

Pathophysiology and therapeutic advances in myeloma bone disease
by: Fujing Zhang, et al.
Published: (2022-12-01)

Health-related quality of life in patients with multiple myeloma on novel agents: Report from a tertiary cancer center in rural India
by: Vineetha Raghavan, et al.
Published: (2018-01-01)

Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women’s health practice
by: Cheung AM, et al.
Published: (2016-09-01)

Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma
by: Anna Mansour, et al.
Published: (2017-08-01)